Estradiol / Norethindrone Dosage

Usual Adult Dose for Atrophic Urethritis

One (1 mg estradiol/0.5 mg norethindrone or 0.5 estradiol/ 0.1 mg norethindrone) tablet orally once a day.

-or-

One (0.05 mg-0.14 mg) patch applied twice weekly. If a greater progestin dose is desired, a single (0.05 mg-0.25 mg) patch may be applied twice weekly.

Alternatively, either patch may be applied as a continuation to an initial 14-day application of an estradiol-only transdermal patch within a 28-day cycle.

The patch should not be applied to, or near, the breasts. The application site should be smooth, clean, dry, fold-free, without damage or irritation, and be rotated with an interval of at least one week allowed to pass between applications to the same site.

If a patch dislodges, it may be reapplied to another area of the lower abdomen, or a new patch may be applied, in which case, the original treatment schedule resumes. However, only one patch should be worn at any given time during the three to four day dosing interval.

Usual Adult Dose for Atrophic Vaginitis

One (1 mg estradiol/0.5 mg norethindrone or 0.5 estradiol/ 0.1 mg norethindrone) tablet orally once a day.

-or-

One (0.05 mg-0.14 mg) patch applied twice weekly. If a greater progestin dose is desired, a single (0.05 mg-0.25 mg) patch may be applied twice weekly.

Alternatively, either patch may be applied as a continuation to an initial 14-day application of an estradiol-only transdermal patch within a 28-day cycle.

The patch should not be applied to, or near, the breasts. The application site should be smooth, clean, dry, fold-free, without damage or irritation, and be rotated with an interval of at least one week allowed to pass between applications to the same site.

If a patch dislodges, it may be reapplied to another area of the lower abdomen, or a new patch may be applied, in which case, the original treatment schedule resumes. However, only one patch should be worn at any given time during the three to four day dosing interval.

Usual Adult Dose for Hypoestrogenism

One (1 mg estradiol/0.5 mg norethindrone or 0.5 estradiol/ 0.1 mg norethindrone) tablet orally once a day.

-or-

One (0.05 mg-0.14 mg) patch applied twice weekly. If a greater progestin dose is desired, a single (0.05 mg-0.25 mg) patch may be applied twice weekly.

Alternatively, either patch may be applied as a continuation to an initial 14-day application of an estradiol-only transdermal patch within a 28-day cycle.

The patch should not be applied to, or near, the breasts. The application site should be smooth, clean, dry, fold-free, without damage or irritation, and be rotated with an interval of at least one week allowed to pass between applications to the same site.

If a patch dislodges, it may be reapplied to another area of the lower abdomen, or a new patch may be applied, in which case, the original treatment schedule resumes. However, only one patch should be worn at any given time during the three to four day dosing interval.

Usual Adult Dose for Postmenopausal Symptoms

One (1 mg estradiol/0.5 mg norethindrone or 0.5 estradiol/ 0.1 mg norethindrone) tablet orally once a day.

-or-

One (0.05 mg-0.14 mg) patch applied twice weekly. If a greater progestin dose is desired, a single (0.05 mg-0.25 mg) patch may be applied twice weekly.

Alternatively, either patch may be applied as a continuation to an initial 14-day application of an estradiol-only transdermal patch within a 28-day cycle.

The patch should not be applied to, or near, the breasts. The application site should be smooth, clean, dry, fold-free, without damage or irritation, and be rotated with an interval of at least one week allowed to pass between applications to the same site.

If a patch dislodges, it may be reapplied to another area of the lower abdomen, or a new patch may be applied, in which case, the original treatment schedule resumes. However, only one patch should be worn at any given time during the three to four day dosing interval.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Hepatic metabolism of estrogens may be impaired in patients with liver disease and clinical monitoring of patient response, tolerance, and liver function is recommended.

Dialysis

Data not available